Market closedADR

Teva Pharmaceutical/$TEVA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Teva Pharmaceutical

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Ticker

$TEVA
Sector
Health Care

Trading on

NYSE

Industry

Pharmaceuticals

Headquarters

Tel Aviv, Israel

Employees

37,000
Website
www.tevapharm.com

TEVA Metrics

BasicAdvanced
$23B
-
-$0.86
0.80
-

$23B

0.8

$22.80

$10.83

11M

0.893

0.491

261.513

301.927

4.04%

5.56%

-17.52%

1.374

3.82

-1.56

16.843

9.81%

-59.05%

1.10%

9.07%

What the Analysts think about TEVA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.

TEVA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TEVA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

TEVA News

AllArticlesVideos
Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Seeking Alpha·1 day ago
Teva Pharmaceuticals CEO talks Trump and US healthcare

Teva Pharmaceuticals CEO talks Trump and US healthcare

Yahoo Finance·1 day ago
Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TEVA

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Teva Pharmaceutical stock?

Teva Pharmaceutical (TEVA) has a market cap of $23B as of January 15, 2025.

What is the P/E ratio for Teva Pharmaceutical stock?

The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 0 as of January 15, 2025.

Does Teva Pharmaceutical stock pay dividends?

No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Teva Pharmaceutical dividend payment date?

Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Teva Pharmaceutical?

Teva Pharmaceutical (TEVA) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.